ASX Announcement Phase 2 CERE-CALM trial expands into Victoria § Ethics approval secured for Goulburn Valley Hospital in Victoria, expanding the Phase 2 CERE-CALM clinical trial beyond New South Wales for the first time § Expanded clinical trial network to support patient recruitment, with...
Phase 2 CERE-CALM trial expands into Victoria
Filed with ASX · · 3 pages · English
Summary by 6ix AI
This expansion broadens the clinical trial network, enhancing patient recruitment opportunities across Australia. The company expects to commence treatment for the first patient in the coming weeks, following successful enrolment. The trial evaluates low-intensity focused ultrasound as a potential treatment for behavioral and psychological symptoms of dementia in Alzheimer's patients.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Ceretas
- Quarterly Activities/Appendix 4C Cash Flow Report
- First Patient Enrolled in Phase 2 CERE-CALM Clinical Trial
- Notice of Annual General Meeting/Proxy Form
- Investor Presentation - October 2026
- Date of AGM and Closing Date for Director Nominations